CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it will present new data from its ALN-TTR program at the VIIIth International Symposium on Familial Amyloidotic Polyneuropathy being held in Kumamoto, Japan from November 20-22, 2011. This includes data from its blinded, randomized, placebo-controlled, single dose escalation Phase I clinical trial of ALN-TTR01 in patients with transthyretin (TTR)-mediated amyloidosis (ATTR).
